|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0010711,
umls-concept:C0023473,
umls-concept:C0205164,
umls-concept:C0376249,
umls-concept:C0871261,
umls-concept:C0935989,
umls-concept:C1518321,
umls-concept:C1521991,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2003-10-9
|
|
pubmed:abstractText |
In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:BoltonAnn EAE,
pubmed-author:BranfordSusanS,
pubmed-author:GathmannInsaI,
pubmed-author:GoldmanJohn MJM,
pubmed-author:HensleyMartee LML,
pubmed-author:HochhausAndreasA,
pubmed-author:HughesTim PTP,
pubmed-author:International Randomised Study of Interferon versus STI571 (IRIS) Study...,
pubmed-author:KaedaJaspalJ,
pubmed-author:RadichJerald PJP,
pubmed-author:RudzkiZbigniewZ,
pubmed-author:van HoomissenIris CIC
|
|
pubmed:copyrightInfo |
Copyright 2003 Massachusetts Medical Society
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
9
|
|
pubmed:volume |
349
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1423-32
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14534335-Actuarial Analysis,
pubmed-meshheading:14534335-Adolescent,
pubmed-meshheading:14534335-Adult,
pubmed-meshheading:14534335-Aged,
pubmed-meshheading:14534335-Antineoplastic Agents,
pubmed-meshheading:14534335-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14534335-Cytarabine,
pubmed-meshheading:14534335-Disease-Free Survival,
pubmed-meshheading:14534335-Female,
pubmed-meshheading:14534335-Fusion Proteins, bcr-abl,
pubmed-meshheading:14534335-Humans,
pubmed-meshheading:14534335-Interferon-alpha,
pubmed-meshheading:14534335-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:14534335-Male,
pubmed-meshheading:14534335-Middle Aged,
pubmed-meshheading:14534335-Piperazines,
pubmed-meshheading:14534335-Pyrimidines,
pubmed-meshheading:14534335-Remission Induction,
pubmed-meshheading:14534335-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:14534335-Transcription, Genetic,
pubmed-meshheading:14534335-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
|
|
pubmed:affiliation |
Institute of Medical and Veterinary Science, Adelaide, SA, Australia. timothy.hughes@imvs.sa.gov.au
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
